您好,欢迎访问江苏省农业科学院 机构知识库!

An Intranasal Nanomedicine Functions as Both Potent Broad-spectrum Viral Inhibitor and Quasi-Vaccine

文献类型: 外文期刊

作者: Chen, Jingran 1 ; Li, Ying 1 ; Xiao, Li 2 ; Guo, Zhanchen 1 ; Lu, Weihua 1 ; Huang, Jin 2 ; Li, Jizong 2 ; Li, Bin 2 ; Liu, Zhen 1 ;

作者机构: 1.Nanjing Univ, Sch Chem & Chem Engn, State Key Lab Analyt Chem Life Sci, Nanjing 210023, Peoples R China

2.Jiangsu Acad Agr Sci, Key Lab Vet Biol Engn & Technol, Jiangsu Key Lab Food Qual & Safety, Minist Agr,Inst Vet Med,State Key Lab Cultivat Bas, Nanjing 210014, Peoples R China

关键词: antiviral; broad-spectrum viral inhibition; glycan shield; photothermal nanomedicine; vaccine

期刊名称:ADVANCED FUNCTIONAL MATERIALS ( 影响因子:19.0; 五年影响因子:19.4 )

ISSN: 1616-301X

年卷期: 2025 年 35 卷 28 期

页码:

收录情况: SCI

摘要: Antivirals that exert rapid inhibition and vaccines that provide long-term prevention are both of paramount importance for the intervening against fatal viral infections. Clearly, it will be highly desirable to integrate the two strategies into a single antiviral agent; however, such a concept is challenging to achieve and has not been explored yet. Herein, an unprecedented broad-spectrum antiviral photothermal nanomedicine is reported with unique advantages to offer both rapid protection and vaccine-like prevention. This nanomedicine is a rationally engineered photothermal gold nanorod capable of targeting the glycan-shield of various viruses and exerting multiple unparalleled antiviral mechanisms, i.e., blocking virus-cell attachment, inducing viral aggregation, enhancing macrophage phagocytosis, promoting virions lysis, and initiating immune response. As such, it exhibits potent and broad-spectrum antiviral efficacy toward a variety of viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its major variants, lassa virus (LASV) and porcine deltacoronavirus (PDCoV), with EC(50 )value as low as tens of pM level and nearly 100% inhibition rate. Significantly, in vivo intranasal administration against authentic PDCoV virus challenge demonstrates rapid virus killing, effective inflammation suppression and production of protective IgA and IgG. Thus, as a proof-of-concept, this study provides new insights and evidences for the design of "two-way player" antiviral agents that can simultaneously treat and prevent viral infections.

  • 相关文献
作者其他论文 更多>>